thisdrug what a medicine's name tells you

WHO naming stem · suffix · 24 listed names

-rubicin

This page was written with AI.

antineoplastics, daunorubicin derivatives

WHO's definition, quoted as written in the 2024 stem book

5 of 24 names appear in these lists: 5 in the US list (FDA Drugs@FDA) and 2 in the EU central list (EMA); 4 have national brands in at least one EU/EEA country.

Names only. This page is about -rubicin as a part of a name. It has nothing on uses, doses, side effects or interactions of any medicine that carries it, and nothing here is medical advice. Ask a pharmacist or doctor about the medicine itself.

Where it sits in a name

WHO writes the stem as -rubicin. So the letters rubicin sit at the end of the name (…rubicin).

All 24 names WHO lists under -rubicin

These are the INN in group (a) of Part IV of the stem book: names in which WHO says the stem is used as defined. The stem is marked where WHO places it. A-Z as WHO lists them.

Beside each name: the brand names it appears under in the US list (FDA Drugs@FDA) and the EU central list (EMA), or that neither list carries it. 5 of 24 names appear in these lists: 5 in the US list (FDA Drugs@FDA) and 2 in the EU central list (EMA); 4 have national brands in at least one EU/EEA country. Each brand opens in this site's brand lookup. A name is found when the agency's ingredient name is the same name once salt words such as hydrochloride or sodium are set aside (the list of those words); where WHO's own name carries such a word (estradiol valerate), the agency must write the same words. A spelling that differs only by the INN letter rules (ph for f, y for i) is found too and shown. Under each name that one or more EU/EEA countries authorise under a national brand of their own (through that country's agency, so not in the EU central list), a line now gives the number of those countries and their codes, from EMA's Article 57 data, and opens the country lookup at that name. A name with none of these lines may still be sold elsewhere, or in Europe only under its own generic name.

  1. aclarubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  2. aldoxorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  3. amrubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  4. berubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  5. camsirubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  6. carubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  7. daunorubicin
    US brands: CERUBIDINE, DAUNOXOME (discontinued in FDA listings)
    in combination: VYXEOS with cytarabine
    EU (central) brands, in combination: Vyxeos liposomal with cytarabine
  8. detorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  9. doxorubicin
    US brands: DOXIL (LIPOSOMAL), ADRIAMYCIN PFS (discontinued in FDA listings), RUBEX (discontinued in FDA listings)
  10. epirubicin
    US brands: ELLENCE
    EU (central) brands: none found
  11. esorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  12. galarubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  13. idarubicin
    US brands: IDAMYCIN PFS, IDAMYCIN (discontinued in FDA listings)
    EU (central) brands: none found
  14. ladirubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  15. leurubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  16. medorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  17. nemorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  18. pidorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  19. pirarubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  20. rodorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  21. sabarubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  22. valrubicin
    EU (central) brands: none found
  23. zoptarelin doxorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)
  24. zorubicin
    Not found in the US or EU-central lists (checked 2026-09-23 and 2026-09-24)

US list: Drugs@FDA, from the FDA Drugs@FDA data (openFDA bulk file), checked . It keeps discontinued brands, marked here as FDA marks them.

EU (central) list: EMA medicines list, European Medicines Agency (EMA), checked . Medicines authorised for the whole EU through EMA only: a brand authorised by one country's own agency is not in it. Source: European Medicines Agency (EMA), medicines list, checked 2026-09-24.

EU/EEA national lists: European Medicines Agency (EMA), Article 57 product data, downloaded (EMA's Article 57 page). Brand names authorised by each country's own agency, as the country lookup reads them; a product named after its substance and maker ("Paracetamol Teva") is not counted as a brand, and EU central authorisations are not counted as a country. GB in a list is Northern Ireland, which EMA's data carries alongside the EU/EEA countries.

Decode another name

Decoded

amrubicin

Listed INNCarries the WHO stem -rubicin

  • -rubicinend of the nameWHO lists it hereWHO definition: antineoplastics, daunorubicin derivatives

“amrubicin” is an INN that WHO lists under -rubicin in the 2024 stem book.

The same decoder as the front page: it reads the letters of a name against all 482 WHO stems, in your browser.

Source and licence

The definition of -rubicin (Part II B) and the 24 names (Part IV, group (a)) are from Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024 (World Health Organization, Stem book 2024 (ISBN 978-92-4-009938-8); covers proposed INN Lists 1-129). Checked .

Adapted from: Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO. This adaptation was not created by WHO; WHO is not responsible for its content or accuracy and does not endorse this site. The data file stems.json is shared under the same licence.

Made with AI tools. · Privacy